JP7661315B2 - 高フェニルアラニン血症の治療方法 - Google Patents

高フェニルアラニン血症の治療方法 Download PDF

Info

Publication number
JP7661315B2
JP7661315B2 JP2022518780A JP2022518780A JP7661315B2 JP 7661315 B2 JP7661315 B2 JP 7661315B2 JP 2022518780 A JP2022518780 A JP 2022518780A JP 2022518780 A JP2022518780 A JP 2022518780A JP 7661315 B2 JP7661315 B2 JP 7661315B2
Authority
JP
Japan
Prior art keywords
day
sepiapterin
subject
pharmaceutical composition
micromoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022518780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549834A5 (https=
JP2022549834A (ja
Inventor
スミス，ニール
Original Assignee
ピーティーシー セラピューティクス エムピー，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス エムピー，インコーポレイテッド filed Critical ピーティーシー セラピューティクス エムピー，インコーポレイテッド
Publication of JP2022549834A publication Critical patent/JP2022549834A/ja
Publication of JP2022549834A5 publication Critical patent/JP2022549834A5/ja
Priority to JP2025061214A priority Critical patent/JP2025111476A/ja
Application granted granted Critical
Publication of JP7661315B2 publication Critical patent/JP7661315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022518780A 2019-09-25 2020-09-25 高フェニルアラニン血症の治療方法 Active JP7661315B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061214A JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
US62/905,720 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061214A Division JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Publications (3)

Publication Number Publication Date
JP2022549834A JP2022549834A (ja) 2022-11-29
JP2022549834A5 JP2022549834A5 (https=) 2023-10-02
JP7661315B2 true JP7661315B2 (ja) 2025-04-14

Family

ID=72827023

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022518780A Active JP7661315B2 (ja) 2019-09-25 2020-09-25 高フェニルアラニン血症の治療方法
JP2025061214A Pending JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061214A Pending JP2025111476A (ja) 2019-09-25 2025-04-02 高フェニルアラニン血症の治療方法

Country Status (22)

Country Link
US (1) US20220362249A1 (https=)
EP (1) EP4034122B1 (https=)
JP (2) JP7661315B2 (https=)
KR (1) KR20220070477A (https=)
CN (1) CN114650825A (https=)
BR (1) BR112022003719A2 (https=)
CA (1) CA3150003A1 (https=)
DK (1) DK4034122T3 (https=)
ES (1) ES3041002T3 (https=)
FI (1) FI4034122T3 (https=)
HR (1) HRP20251268T1 (https=)
HU (1) HUE073483T2 (https=)
IL (1) IL291565B1 (https=)
JO (1) JOP20220042A1 (https=)
LT (1) LT4034122T (https=)
MX (1) MX2022003585A (https=)
PL (1) PL4034122T3 (https=)
PT (1) PT4034122T (https=)
RS (1) RS67295B1 (https=)
SI (1) SI4034122T1 (https=)
SM (1) SMT202500493T1 (https=)
WO (1) WO2021062264A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) * 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Clinica Chimica Acta，1979年，Vol.93，pp.251-262
Eur J Pediatr，1982年，Vol.138，pp.110-112
J. Inher. Metab. Dis.，1982年，Vol.5，pp.81-82
Molecular Genetics and Metabolism，2019年02月10日，Vol.126，pp.406-412
The Lancet，1979年，Volume 313, Issue 8108，pp.131-133

Also Published As

Publication number Publication date
SMT202500493T1 (it) 2026-01-12
SI4034122T1 (sl) 2025-12-31
IL291565B1 (en) 2026-04-01
AU2020353676A1 (en) 2022-04-14
HUE073483T2 (hu) 2026-01-28
FI4034122T3 (fi) 2025-10-08
IL291565A (en) 2022-05-01
CA3150003A1 (en) 2021-04-01
DK4034122T3 (da) 2025-09-15
LT4034122T (lt) 2025-11-10
JP2025111476A (ja) 2025-07-30
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
MX2022003585A (es) 2022-04-19
CN114650825A (zh) 2022-06-21
EP4034122A1 (en) 2022-08-03
ES3041002T3 (en) 2025-11-06
US20220362249A1 (en) 2022-11-17
EP4034122B1 (en) 2025-08-13
RS67295B1 (sr) 2025-11-28
BR112022003719A2 (pt) 2022-05-31
KR20220070477A (ko) 2022-05-31
PL4034122T3 (pl) 2026-01-26

Similar Documents

Publication Publication Date Title
JP7661315B2 (ja) 高フェニルアラニン血症の治療方法
JP7442095B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
RU2356247C2 (ru) Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор
JP2023116556A (ja) セピアプテリンを含む医薬組成物及びその使用
EP3801534B1 (en) Treatment of phenylketonuria with sepiapterin
WO2020044163A1 (en) Methods of normalizing amino acid metabolism
RS65874B1 (sr) Primena sepiapterina bez hrane za upotrebu u postupku za povećanje izloženosti plazme sepiapterinu
AU9780598A (en) Serotonin containing formulation for oral administration and method of use
AU2020353676B2 (en) Methods for treating hyperphenylalaninemia
HK40081378B (en) Methods for treating hyperphenylalaninemia
HK40081378A (en) Methods for treating hyperphenylalaninemia
EA047419B1 (ru) Способы лечения гиперфенилаланинемии
EA052959B1 (ru) Способы лечения гиперфенилаланинемии
JP2024506336A (ja) 膠芽腫の治療方法
CA3165636A1 (en) Methods for treating parkinson's disease with sepiapterin
CN120837471A (zh) 组合物改善高苯丙氨酸血症的用途
WO2022173823A1 (en) Methods for treating covid-19 with sepiapterin
CN102793716A (zh) 脂族胺聚合物的用途及其药物组合物和制备方法
JPH01216931A (ja) 血中尿酸濃度低減用治療剤
US20070072910A1 (en) Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
TW202033199A (zh) 化合物ａ與化合物ｂ聯合在製備治療痛風或高尿酸血症的藥物中的用途
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
Kelemen et al. Central nervous system stimulants and anorectic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250402

R150 Certificate of patent or registration of utility model

Ref document number: 7661315

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150